India Pharma Outlook Team | Friday, 12 June 2026
.jpeg "Cancer Drug Crisis Exposes Stress in India's Price Control Model")
India’s ongoing cancer drug shortage is no longer just a supply disruption, it is increasingly being seen as a structural stress test for the country’s drug price control framework.
While the government has moved to ease pricing restrictions on critical oncology drugs like cisplatin and carboplatin, the episode raises a deeper question: can India’s tightly regulated pricing model sustain itself in a world of volatile global input costs?
India’s drug pricing system has long been designed to ensure affordability, particularly for essential medicines. However, the recent shortage of platinum-based cancer drugs highlights a fundamental trade-off when prices are capped too tightly, they can discourage production.
In this case, a surge in platinum prices driven by global supply constraints and geopolitical disruptions significantly increased manufacturing costs. With limited room to pass on these costs, companies found themselves operating under financial strain, ultimately impacting supply.
This flips the traditional healthcare concern on its head: medicines may remain affordable on paper, but unavailable in reality.
The government’s move to invoke special provisions under the Drugs Price Control Order (DPCO) is notable not just for its impact, but for its rarity.
Such interventions are typically reserved for exceptional situations, indicating that the current disruption is not routine. It also signals that policymakers are increasingly being forced to respond to global cost dynamics something the existing framework was not originally designed to handle.
The fact that only a handful of drugs have been considered for price revision, despite wider industry demand, suggests a cautious approach but also reveals the limits of incremental fixes.
At the heart of the issue is a growing disconnect between globalized supply chains and domestically controlled pricing.
India relies heavily on imported raw materials for several critical drugs. When global prices rise sharply, domestic price caps prevent manufacturers from adjusting accordingly. This creates a structural imbalance, where cost pressures are external but pricing flexibility is internal and restricted.
Over time, such mismatches can lead to recurring supply disruptions, particularly for low-margin essential drugs.
Also Read: Government May Lift Price Cap on Cancer Drugs, Prices May Rise 50%
For pharmaceutical companies, the current situation reinforces the need to rethink product portfolios and manufacturing priorities.
Low-priced, high-volume essential drugs, once seen as stable segments, are increasingly becoming vulnerable to cost shocks. This could push companies to shift focus toward higher-margin therapies or export-oriented markets where pricing is more flexible.
At a broader level, it also raises concerns about India’s long-term positioning as a reliable supplier of affordable medicines.
The current crisis may accelerate discussions around more dynamic pricing models, ones that can respond to input cost fluctuations without waiting for emergency interventions.
Options such as periodic cost-linked revisions, differential pricing mechanisms, or targeted subsidies for critical drugs could emerge as policy alternatives.
The challenge, however, will be maintaining the delicate balance between affordability for patients and viability for manufacturers.
What began as a shortage of two cancer drugs is now evolving into a larger policy debate.
India’s pharmaceutical success has been built on affordable access, but sustaining that model in an increasingly volatile global environment may require structural recalibration.
The real question is no longer just how to control prices, but how to ensure that price control does not come at the cost of access itself.
.jpg)
